CNCR vs. PPH

Last updated Jun 24, 2026

CNCR (Loncar Cancer Immunotherapy ETF) and PPH (VanEck Pharmaceutical ETF) are both Health & Biotech Equities funds - CNCR tracks the Loncar Cancer Immunotherapy Index while PPH tracks the MVIS US Listed Pharmaceutical 25 Index. Both are passively managed. CNCR charges 0.79%/yr vs 0.36%/yr for PPH.

Performance

CNCR vs. PPH - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Loncar Cancer Immunotherapy ETF (CNCR) and VanEck Pharmaceutical ETF (PPH). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

CNCR

• 1D: 0.00%
• 1M: 0.00%
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

PPH

• 1D: 1.79%
• 1M: 0.31%
• YTD: 2.92%
• 6M: 2.77%
• 1Y: 23.31%
• 3Y*: 12.54%
• 5Y*: 9.67%
• 10Y*: 8.52%

*Multi-year figures are annualized to reflect compound growth (CAGR)

CNCR vs. PPH - Yearly Performance Comparison

	2026 (YTD)
CNCR Loncar Cancer Immunotherapy ETF	0.00%
PPH VanEck Pharmaceutical ETF	-1.54%

CNCR vs. PPH - Sectors Allocation Comparison

Sectors	CNCR	PPH
Healthcare	96.6%	100.0%
Financial Services	3.3%	-
Basic Materials	-	-
Communication Services	-	-
Consumer Cyclical	-	-
Consumer Defensive	-	-
Energy	-	-
Industrials	-	0.1%
Real Estate	-	-
Technology	-	-
Utilities	-	-

Return for Risk

CNCR vs. PPH — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CNCR

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

PPH

PPH Risk / Return Rank: 40
PPH Sharpe Ratio Rank: 39
PPH Sortino Ratio Rank: 42
PPH Omega Ratio Rank: 37
PPH Calmar Ratio Rank: 46
PPH Martin Ratio Rank: 36

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CNCR vs. PPH - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Loncar Cancer Immunotherapy ETF (CNCR) and VanEck Pharmaceutical ETF (PPH). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	CNCR	PPH	Difference
Sharpe ratio: Return per unit of total volatility	—	1.33	—
Sortino ratio: Return per unit of downside risk	—	2.07	—
Omega ratio: Gain probability vs. loss probability	—	1.24	—
Calmar ratio: Return relative to maximum drawdown	—	2.18	—
Martin ratio: Return relative to average drawdown	—	5.30	—

Drawdowns

CNCR vs. PPH - Drawdown Comparison

The maximum CNCR drawdown since its inception was 0.00%, smaller than the maximum PPH drawdown of -51.45%. Use the drawdown chart below to compare losses from any high point for CNCR and PPH.

Drawdown Indicators

	CNCR	PPH	Difference
Max Drawdown Largest peak-to-trough decline	0.00%	-51.45%	+51.45%
Max Drawdown (1Y) Largest decline over 1 year	—	-10.76%	—
Max Drawdown (3Y) Largest decline over 3 years	—	-18.06%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-20.26%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-29.70%	—
Current Drawdown Current decline from peak	0.00%	-4.94%	+4.94%
Average Drawdown Average peak-to-trough decline	0.00%	-17.29%	+17.29%
Ulcer Index Depth and duration of drawdowns from previous peaks	—	4.41%	—

Volatility

Volatility by Period

	CNCR	PPH	Difference
Volatility (1M) Calculated over the trailing 1-month period	—	6.27%	—
Volatility (6M) Calculated over the trailing 6-month period	—	12.27%	—
Volatility (1Y) Calculated over the trailing 1-year period	0.00%	17.66%	-17.66%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	0.00%	15.17%	-15.17%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	0.00%	16.98%	-16.98%

CNCR vs. PPH - Expense Ratio Comparison

CNCR has a 0.79% expense ratio, which is higher than PPH's 0.36% expense ratio.

Dividends

CNCR vs. PPH - Dividend Comparison

CNCR has not paid dividends to shareholders, while PPH's dividend yield for the trailing twelve months is around 2.05%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
CNCR Loncar Cancer Immunotherapy ETF	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
PPH VanEck Pharmaceutical ETF	2.05%	1.78%	1.98%	2.09%	1.55%	1.62%	1.66%	1.77%	1.97%	1.92%	2.43%	1.93%

Frequently Asked Questions

Which ETF is better, CNCR or PPH?

On fees, PPH is cheaper at 0.36% per year. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF is cheaper, CNCR or PPH?

PPH is cheaper with a 0.36% expense ratio, compared with 0.79% for CNCR.

Which ETF pays a higher dividend yield, CNCR or PPH?

PPH has the higher dividend yield at 2.05%, compared with 0.00% for CNCR.

What is the main difference between CNCR and PPH?

CNCR tracks Loncar Cancer Immunotherapy Index, while PPH tracks MVIS US Listed Pharmaceutical 25 Index. They also come from different issuers: Exchange Traded Concepts and VanEck. Their fees differ too: 0.79% for CNCR and 0.36% for PPH.